Related Experiment Videos
Secondary hyperparathyroidism exacerbation: a rare side-effect of interferon-alpha?
J Calvino1, R Romero, J M Suárez-Peñaranda
1Division of Nephrology, Complexo Hospitalario Universitario, Santiago de Compostela, Spain.
Clinical Nephrology
|May 7, 1999
Summary
Recombinant human interferon alpha (alpha IFN) treatment for hepatitis C can trigger autoimmune conditions. This case highlights de novo psoriasis and hyperparathyroidism in a patient, resolving after discontinuing alpha IFN.
Area of Science:
- Hepatology
- Immunology
- Nephrology
Background:
- Recombinant human interferon alpha (alpha IFN) is a primary treatment for chronic hepatitis C virus (HCV) infection.
- Alpha IFN can induce or worsen autoimmune conditions in susceptible individuals.
Observation:
- A 20-year-old woman on peritoneal dialysis with chronic lobular hepatitis (HCV) developed new-onset psoriasis.
- This occurred 9 months after initiating alpha IFN therapy.
- She also experienced a refractory exacerbation of secondary hyperparathyroidism, with low serum calcium and high parathyroid hormone (PTH).
Findings:
- Both psoriasis and hyperparathyroidism resolved after alpha IFN treatment was withdrawn.
- The temporal relationship suggests alpha IFN as the causative agent for these adverse events.
Implications:
- This case underscores the potential for alpha IFN to induce autoimmune side effects, including dermatological and endocrine complications.
- Further investigation into the etiopathogenic factors of alpha IFN-induced autoimmunity is warranted.
- Clinicians should monitor for autoimmune manifestations in patients receiving alpha IFN therapy.